Long Island Capital Alliance Announces Highly Successful Biotech Capital Forum
Save the Date: Consumer Products Capital Forum on July 24, 2014
MELVILLE, NY -- (Marketwired) -- 05/15/14 -- The Long Island
Capital Alliance ("LICA"), the leading non-profit capital formation
and business development organization serving regional companies,
today announced the successful completion of its Biotech Capital
Forum held on Friday, May 9, 2014. Held in collaboration with North
Shore-LIJ Health System's Feinstein Institute for Medical Research
and Cold Spring Harbor Laboratory, the event provided an opportunity
to bring together capital providers, entrepreneurs, industry
executives and businesses seeking capital, as well as to hear a panel
of industry experts discuss financing alternatives for biotechnology
companies on Long Island which was moderated by LICA Board Member
Michael A. Lane.
Seven local biotechnology companies presented their business plans to
investors, including attendees from venture capital firms, investment
banks, private equity firms, angel and other individual investors.
Each of the companies LICA selected for presentation at the capital
forum possesses unique technologies and catalysts for significant
growth which are attractive to investors.
"The Long Island Capital Alliance's second annual Biotech Capital
Forum was a resounding success on multiple fronts, and we thank North
Shore-LIJ Health System's Feinstein Institute for Medical Research
and Cold Spring Harbor Laboratory for their contributions," said Neil
Kaufman, Chairman of LICA. "Over 100 attendees joined us for the
three hour event. 14 follow-up dialogues with potential investors
have already been reported to us by five of the presenting companies,
and we are confident that many more will follow. Another benefit of
the capital forum is the opportunity for networking, which in this
case resulted in one of the presenting companies considering engaging
a highly experienced business leader in attendance at the event for
its CEO position."
"This was my first time at a LICA event. I found the presenting
companies to be involved in breakthrough research, their
presentations were engaging and the presenters well prepared. These
companies are definitely worthy of funding. This is a real tribute to
LICA," said Doug Jamison, a panelist and Chief Executive Officer of
biotech investment fund Harris & Harris Group.
"The quality of the presenting companies was excellent, as was the
quality of the discussions after the event. It is clear that Long
Island will continue to be a source of major innovation for a long
time to come," said James Ryan III, a panelist with seed investor and
venture capital firm Scout Ventures.
"The presentation at LICA was a great experience and I enjoyed
meeting with a number of like-minded entrepreneurs," said Pavel
Osten, who presented for Cold Spring Harbor Laboratory's Certerra,
"As an early-stage company seeking to raise capital, CirrusHealth was
pleased to be part of LICA's Capital Forum. The opportunity has led
to a number of high-potential follow-up conversations and was an
excellent networking opportunity," commented Thomas Thornton, who
presented for Feinstein Institute for Medical Research's
"The LICA forum gave us a great opportunity to showcase our company
and network with qualified investors. The forum provides start-up
companies with an invaluable source of connections, promoting
fruitful partnerships," added Isabel Aznarez, Ph.D., who presented
for Cold Spring Harbor Laboratory's ASOThera.
Biotech Capital Forum Presenting Companies
The following companies made presentations at the Long Island Capital
ASOThera: Developing new therapies for orphan diseases based on
technology developed at Cold Spring Harbor Laboratory and already
proven by Big Pharma.
Autoimmune Therapeutics, Inc.: Developing orally-available drug
candidates to treat autoimmune disease, with initial focus on
rheumatoid arthritis, based on proprietary small molecule scaffolds
and pharmaceutical leads that inhibit macrophage migration inhibitory
Certerra, Inc.: Contract research organization specializing in
central nervous system with technology based on single neuron-level
monitoring of mammalian brains.
CirrusHealth: Electronic discharge system to improve doctor patient
DepYMed: Joint venture between CSHL and Ohr Pharmaceuticals (NASDAQ:
OHRP) to develop a drug for obesity, diabetes and HER2 cancer based
on trodusquemine and related analogs.
Envisagenics, Inc.: Big data software solution that significantly
reduces uncertainty and time to market for drugs under development.
TheraSource, LLC: Developing protein/peptide-based drugs based on
MFG-E8 for inflammatory diseases, including sepsis, hemorrhagic
shock, ischemia/reperfusion-induced injury, stroke, acute radiation
syndrome, rheumatoid arthritis, and inflammatory bowel disease.
Biotech Capital Forum Panel of Industry Investors
The following investment professionals participated in the panel
discussion at the Long Island Capital Forum:
Doug Jamison, Harris & Harris Group: Doug Jamison is Chairman and
Chief Executive Officer of Harris & Harris Group (NASDAQ: TINY), a
leading early stage biotech investment fund. He is a member of the
Board of Directors of Ancora Pharmaceuticals, Inc., and a Board
observer in ABS Materials, Inc., Mersana Therapeutics, Inc.,
Solazyme, Inc., Nextreme Thermal Solutions, Inc., and Metabolon, Inc.
James Ryan III, Scout Ventures: James Ryan is Controller at Scout
Ventures, a technology seed and venture fund. In addition, he is the
Founder and CEO of The IllumiFi Group, an 'Outsourced CFO' for
Joe Proto, Windham Venture Partners: Joe Proto is a founder and
general partner of Windham Venture Partners, a leading life sciences
technology venture capital firm. He also is Chairman and Chief
Executive Officer of Transactis Inc., sits on the Board of Directors
of BillMyParents, and is a limited partner and advisor in Metamorphic
Steve Winick, Topspin Partners: Steve Winick is a principal of
Topspin Partners, one of Long Island's leading venture capital firms.
He presently serves as a Director of Thermolift, Inc., Celmatix,
Inc., Setpoint Medical, Inc., Mirimus, Inc., GenDX, Inc. and
Next LICA Capital Forum
LICA is hosting a Consumer Products Capital Forum on Thursday, July
24, 2014 from 8:00 a.m. to 11:00 a.m. at 68 South Service Road,
Melville, NY. The capital forum provides an opportunity to meet
capital providers, entrepreneurs, industry executives and businesses
seeking capital, as well as to hear a panel of industry experts
discuss financing alternatives for consumer products companies.
For more information about the event, please contact LICA today or
About the Long Island Capital Alliance
Since 1984, the Long Island Capital Alliance (www.licapital.org),
formerly known as Long Island Venture Group, has been promoting
business growth on Long Island. LICA seeks to create a productive and
business-friendly environment that will afford area businesses access
to the resources necessary to compete successfully in today's
markets. LICA serves as a focal point for the exchange of ideas among
new and existing business enterprises, successful entrepreneurs,
investors, and service providers. Through quarterly capital forums
and special meetings, LICA brings together members of the region's
business community, and has been recognized
as the place to turn to
when small businesses need equity, debt, or other financing, or for
investors to find an attractive investment opportunity.
LICA's mission is to encourage economic development on Long Island by
facilitating capital formation for a broad range of companies in
various industries, from early stage to mature, middle market,
closely held and publicly-traded businesses. LICA accomplishes this
primarily through education, networking, quarterly capital forums,
periodic special educational meetings, and alliances with other
regional organizations. LICA brings together members of the region's
business community and serves as the finance arm for significant
local business and organizations.
For more information on LICA and its next event, please contact LICA
today or register online.
About The Feinstein Institute for Medical Research
Manhasset, NY, The Feinstein Institute for Medical Research is home
to international scientific leaders in many areas including
Parkinson's disease, Alzheimer's disease, psychiatric disorders,
rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary
hypertension, leukemia, neuroimmunology, and medicinal chemistry. The
Feinstein Institute, part of the North Shore-LIJ Health System, ranks
in the top 6th percentile of all National Institutes of Health grants
awarded to research centers. For more information, visit
About Cold Spring Harbor Laboratory
Founded in 1890, Cold Spring
Harbor Laboratory (CSHL) has shaped contemporary biomedical research
and education with programs in cancer, neuroscience, plant biology
and quantitative biology. CSHL is ranked number one in the world by
Thomson Reuters for impact of its research in molecular biology and
genetics. The Laboratory has been home to eight Nobel Prize winners.
Today, CSHL's multidisciplinary scientific community is more than 600
researchers and technicians strong and its Meetings & Courses program
hosts more than 12,000 scientists from around the world each year to
its Long Island campus and its China center. Tens of thousands more
benefit from the research, reviews, and ideas published in journals
and books distributed internationally by CSHL Press. The Laboratory's
education arm also includes a graduate school and programs for
undergraduates as well as middle and high school students and
teachers. CSHL is a private, not-for-profit institution on the north
shore of Long Island. For more information, visit www.cshl.edu.
Darrow Associates, Inc.
Press spacebar to pause and continue. Press esc to stop.